Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exploring the therapeutic potential of human umbilical cord mesenchymal stem cells derived extracellular vesicles in cancer immunotherapy

Dehghani F., Daghaighei M., Azani A., Mahdizadeh MA., Takhtizadeh MM., Mehrdad Z.

Narrative Review on Immune Modulation, published in Discov Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Discov Oncol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41353465
PMCID
PMC12921072
DOI
10.1007/s12672-025-04156-w

Abstract (original English)

The therapeutic potential of human umbilical cord mesenchymal stem cells derived extracellular vesicles (hUCMSC-EVs) in cancer immunotherapy is an emerging area of research that offers promising avenues for enhancing treatment efficacy. This review explores the distinct characteristics of hUCMSC-EVs, highlighting their unique composition and functional properties that differentiate them from extracellular vesicles derived from other sources. We compared the immunomodulatory effects of MSCs derived from the umbilical cord with those of MSCs derived from alternative sources, highlighting their superior therapeutic potential in cancer therapy. Furthermore, we examined the impact of hUCMSC-EVs on cancer cells and the tumor microenvironment, elucidating the mechanisms of signaling pathways involved in their effects. Recent advances in the application of hUCMSC-EVs have yielded encouraging therapeutic outcomes, highlighting several advantages over conventional cancer immunotherapies. However, challenges remain in the translational application of these therapies, including variability in EV production, pharmacokinetics, and standardization of protocols, necessitating further research to overcome barriers and optimize their clinical implementation. This review uniquely focuses on the therapeutic implications of hUCMSC-EVs in cancer immunotherapy, highlighting their distinct advantages

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research